Ketamine for Major Depressive Disorder

Phase-Based Progress Estimates
Royal University Hospital, Saskatoon, CanadaMajor Depressive Disorder+1 MoreKetamine - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether a high-intensity ketamine treatment approach can help people with treatment-resistant depression, by reducing symptoms, side effects, and the need for ECT.

Eligible Conditions
  • Major Depressive Disorder
  • Ketamine

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: From date of randomization until the date of disease remission or after 8 treatments and at 30 days following last treatment, assessed up to 8 weeks

Week 8
Patient satisfaction with treatment
Self- and clinician rated improvement
Suicidal ideation
Week 4
Number of treatments required to reach disease remission
Day 6
Rate of rescue ECT in the HIKER arm
Day 30
Cognitive Impairment

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Ketamine-ECT (EAST)
1 of 2
Ketamine (HIKER)
1 of 2

Active Control

Experimental Treatment

62 Total Participants · 2 Treatment Groups

Primary Treatment: Ketamine · No Placebo Group · Phase 4

Ketamine (HIKER)
Experimental Group · 1 Intervention: Ketamine · Intervention Types: Drug
Ketamine-ECT (EAST)ActiveComparator Group · 2 Interventions: Ketamine, ECT · Intervention Types: Drug, Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from date of randomization until the date of disease remission or after 8 treatments and at 30 days following last treatment, assessed up to 8 weeks

Who is running the clinical trial?

University of SaskatchewanLead Sponsor
239 Previous Clinical Trials
89,847 Total Patients Enrolled
Royal University Hospital FoundationOTHER
22 Previous Clinical Trials
6,809 Total Patients Enrolled
Jonathan Gamble, MDPrincipal InvestigatorUniversity of Saskatchewan
4 Previous Clinical Trials
464 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
New York100.0%
What site did they apply to?
Royal University Hospital100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

Frequently Asked Questions

Has the FDA granted official authorization to use Ketamine?

"We have rated Ketamine's safety as a 3, signifying that it has been approved by the FDA and is safe to use in Phase 4 clinical trials." - Anonymous Online Contributor

Unverified Answer

What is the number of people being recruited to participate in this medical experiment?

"Affirmative. Per the records uploaded on, this medical experiment is currently seeking volunteers. The trial was first listed on September 1st 2017 and most recently updated on October 31st 2022, with 62 patients being sought from a single hospital institution." - Anonymous Online Contributor

Unverified Answer

Is enrollment for this clinical research still open at present?

"Per the information currently available on, this trial is still actively looking for participants and has been since its initial posting on September 1st 2017 with a recent update occurring October 31st 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.